Cleave Therapeutics

Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.

Launch date

2011

Employees

Market cap

Enterprise valuation

San Francisco California (HQ)

Date	Investors	Amount	Round
Oct 2011	5AM Ventures	$44.0m	Series A
Apr 2013	New Enterprise Associates	$10.0m	Series A
Apr 2013	New Enterprise Associates	$10.0m	Series A
Apr 2016	Imperial Create Lab	N/A	-
Aug 2016	New Enterprise Associates Arcus Ventures 5AM Ventures Clarus Ventures Celgene OrbiMed Nextech Invest	$26.0m	Series B
Aug 2016	New Enterprise Associates Nextech Invest	$26.0m	Series B
Aug 2019	Arcus Ventures 5AM Ventures U.S. Venture Partners Bristol-Myers Squibb Celgene OrbiMed Astellas Venture Osage Univ. Partners	$12.0m	Series C
Total Funding		€116m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Cleave Therapeutics